Johanna Friedl-Naderer, Chief Commercial Officer at Dyne Therapeutics, Inc. (DYN), sold 148 shares at $14.90 ($2K) on 2026-03-05, disclosed to the SEC on 2026-03-06.
Scheduled sale ($2k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DYN | SELL | 2026-06-17 | $3K | — | Filing → |
| DYN | SELL | 2026-05-14 | $4K | — | Filing → |
| DYN | SELL | 2025-12-05 | $3K | — | Filing → |